Backgroud/Aims: Besides its anti-allergic properties as a histamine receptor antagonist, olopatadine stabilizes mast cells by inhibiting the release of chemokines. Since olopatadine bears amphiphilic features and is preferentially partitioned into the lipid bilayers of the plasma membrane, it would induce some morphological changes in mast cells and thus affect the process of exocytosis. Methods: Employing the standard patch-clamp whole-cell recording technique, we examined the effects of olopatadine and other anti-allergic drugs on the membrane capacitance (Cm) in rat peritoneal mast cells during exocytosis. Using confocal the deformation of the plasma membrane. Results: Low concentrations of olopatadine (1 or 10 -S-induced increase in the Cm. However, 100 M and 1 mM olopatadine almost totally suppressed the increase in the Cm. Additionally, these doses completely washed out the trapping of the dye on the cell surface, indicating that olopatadine counteracted the membrane surface deformation induced by exocytosis. As shown by electron microscopy, olopatadine generated inward membrane bending in mast cells. Conclusion: olopatadine dose-dependently inhibits the process of exocytosis in rat peritoneal mast cells. Such mast cell stabilizing properties of olopatadine may be attributed to its counteracting effects on the plasma membrane deformation in degranulating mast cells.
Introduction
Olopatadine is one of the most potent anti-allergic drugs that are widely used in the treatment of allergic disorders, such as seasonal pollinosis, chronic rhinitis, urticaria and allergic conjunctivitis. Olopatadine was originally developed as a second-generation antihistamine drug [1] , which was to thought to exert its anti-allergic effects primarily by antagonizing histamine H1 receptors. Additionally, studies using human conjunctival mast cells further demonstrated that this drug also exerts inhibitory effects on the release of chemokines [2] [3] [4] . Concerning the mechanisms by which drugs exert such mast cell stabilizing properties, previous studies indicated that the drug-induced changes in the intracellular Ca 2+ concentration ([Ca 2+ ] i ) are primarily responsible [5, 6] . However, later studies also revealed the involvement of G proteins [7] or mechanical stimuli to the plasma membranes [8] in modulating the process of exocytosis in mast cells. In our recent study, chlorpromazine, a positively charged membrane amphipath, changed the plasma membrane curvature in rat inhibited the process of exocytosis. Since olopatadine, a relatively cationic and lipophilic antihistamine, shares common pharmacological features with those of the membrane amphipaths [10] , this drug should also induce some morphological changes in mast cell plasma membranes, and thus may affect their exocytotic process. To test this, employing the standard patch-clamp whole-cell recording technique in rat peritoneal mast cells [9, 11, 12] , we examined the effects of olopatadine on the membrane capacitance. By confocal also examined the effects of this drug on the plasma membrane deformation. Here, using olopatadine dose-dependently inhibits the process of exocytosis. We also show that such mast cell stabilizing properties of olopatadine can be ascribed to its counteracting effects on the plasma membrane deformation in degranulating mast cells.
Materials and Methods

Cell Sources and Preparation
Male Wistar rats more than 25 weeks old, supplied by Japan SLC Inc. (Shizuoka, Japan), were deeply approved by the Animal Care and Use Committee of Tohoku University Graduate School of Medicine. Peritoneal mast cells were obtained by washing the peritoneal cavity with standard external (bathing) solution containing (in mM): NaCl, 145; KCl, 4.0; CaCl 2 , 1.0; MgCl 2 , 2.0; HEPES, 5.0; bovine serum albumin, 0.01 % (pH 7.2 adjusted with NaOH) as described in our previous study [9] . They were maintained at room temperature (22) (23) (24) for use within 8 hours. The mast cell suspension was scattered in a chamber placed on the headstage of an inverted microscope (Nikon, Tokyo, Japan). Single mast cells were easily distinguishable from other cells by their intracellular inclusion of secretory granules [9] .
Olopatadine hydrochloride, kindly provided by Kyowa Hakko Kirin Co., Ltd. (Tokyo, Japan), was M and 1 mM, respectively. Fexofenadine hydrochloride, purchased from LKT Laboratories, Inc. (St. Paul, Min., USA), and loratadine, from Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan), were also separately dissolved in the external solution at M. After mast cells were incubated in these solutions or a solution containing concentration 10 2 view (10 views from 6 of each condition), as described in our previous studies [9, 14] . Degranulated mast 8 granules outside the cell membrane, as described previously [15] . These mast cells were then counted and their ratio to all mast cells was calculated.
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Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry system (HEKA Electronics, Lambrecht, Germany) as described previously [9, 16] . The patch pipette resistance 2 , 2.0; Hepes, 5.0 (pH 7.2 adjusted with KOH). One-hundred M guanosine 5'-o -S) (EMD Bioscience Inc., La Jolla, CA, USA) was additionally included in the internal solution to induce exocytosis in the mast cells [9, 11, 12] . After a giga-seal formation on mast cells scattered in the external solutions containing no drug, the different concentrations of olopatadine (1, 10, 100 M and 1 mM), 100 M dialyze the cells with GTP--S. The series resistance of the whole-cell recordings was maintained below 10
voltage was superimposed on the holding potential of -80 mV. The membrane capacitance (Cm), as well as membrane conductance (Gm) and series conductance (Gs), was continuously recorded during the wholeAfter the mast cells were incubated in the external solutions containing no drug, the different concentrations of olopatadine (1, 10, 100 M and 1 mM), 100 M fexofenadine or loratadine, exocytosis was externally induced by compound 48/80 (10 g/ml). Then, the cells were incubated for 5 min at room solutions. Fluorescent images were taken using a TE 2000-E Nikon Eclipse confocal microscope (Nikon, Tokyo, Japan).
The mast cells, incubated in the external solutions containing no drug or 1mM olopatadine for 10 at room temperature. After being trimmed into small pieces, the above specimen containing the cells was ultramicrotome (Ultracut R, Leica, Heerbrugg, Switzerland) with a diamond knife and then were stained with uranyl acetate and lead citrate, and viewed using an electron microscope (JEM-1200, JOEL, Tokyo, Japan).
Data were analyzed using PulseFit software (HEKA Electronics, Lambrecht, Germany) and Microsoft was assessed by two-way ANOVA followed by Dunnett's or Student's t test. A value of p < 0.05 was considered
Results
In the absence of olopatadine, compound 48/80 (10 g/ml) induced degranulation in 80.5 ± 1.1 % of the mast cells observed (n=6). In human, the physiological plasma concentration of olopatadine ranges from 1 to 10 M when orally administered for the treatment of systemic allergic reactions [17] [18] [19] . On the other hand, when topically M olopatadine were required to effectively elicit its inhibitory propeties on histamine release from human conjunctival mast cells [2] [3] [4] . Since doses as high as 10 mM did not cause any cytotoxic effects in a previous in vitro study [20] , we tried doses starting from 1 M up to 1 mM in the present study. Relatively lower concentrations of olopatadine, such as 1 and 10 M, did not Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry 100 M and 1 mM markedly decreased the numbers of degranulating mast cells (100 M, 17.1 ± 1.8 %; 1 mM, 10.6 ± 0.55 %; n=6, P<0.05; Fig. 1A ). From our results, olopatadine, which is also known as a mast cell stabilizer [21] , actually inhibited the degranulation from rat peritoneal mast cells in a concentration-dependent manner. These results were consistent dose-dependently inhibited the release of histamine [2] [3] [4] . Besides olopatadine, some anti-allergic drugs are also known to exert mast cell stabilizing properties than olopatadine does [22, 25] . Therefore, we also examined the effects of these drugs on the degranulation of mast cells (Fig. 1B) . As expected, fexofenadine solution alone: 81.4 ± 1.4 %, n=6, Fig. 1B ), but loratadine markedly decreased the number of n=6, P<0.05).
In megakaryocytes or thymus lymphocytes, microscopic changes in the cell surface area were induced by membrane invagination during thrombopoiesis [26] or by the accumulation of lipophilic drugs into the lipid bilayers [27] . In our previous studies, such microscopic changes in these cells were most precisely monitored by measurement of the that the increase in the Cm well indicates the degranulating process during exocytosis [9, exocytosis, we incubated the cells in olopatadine-containing external solutions and examined the changes in the Cm (Fig. 2) . The effects of different concentrations of olopatadine on the with 100 M or 1 mM olopatadine almost completely suppressed the incremental effect of GTP--S on the Cm (Fig. 2C and D, Table 1 ). As previously shown in degranulating mast cells pipette electrodes and the cells interior. These results provide electrophysiological evidence
We also examined the effects of loratadine and fexofenadine on the Cm (Table 1) , since these drugs inhibited or failed to inhibit the degranulation of mast cells (Fig. 1B) . In mast cells incubated with 100 0.61 to 24.4 ± 1.79 pF, n=6, P<0.05; Table 1 ). However, in mast cells incubated with 100 M ± 1.61 pF, n=6; Table 1 ).
In our recent study, amphiphilic drugs, such as salicylate and chlorpromazine, changed the plasma membrane curvature in rat peritoneal mast cells [9] , which modulated the process of exocytosis. In the present study, since olopatadine inhibited the exocytotic process in mast cells (Fig. 1, 2) , the drug-induced morphological changes in the cells would also affect this process. Therefore, after incubating mast cells in fexofenadine, loratadine or olopatadinecontaining solutions, we externally induced exocytosis in the cells and examined the effects mast cells incubated in the external solution showed more wrinkles on their cell surface and in 100 M olopatadine-containing solutions ( the wrinkles on their cell surface and the release of secretory granules, were totally absent. To determine whether the wrinkles observed in the degranulating mast cells (Fig.  Ab,c,e,f) represented membrane surface deformation as a result of exocytosis, we then used olopatadine solution (1 and 10 M and 1 mM olopatadine-containing solutions 5 . Illustrations of the olopatadineinduced plasma membrane curvature and the proposed effects on mast cell exocytosis. A: Positively charged (+; cationic) olopatadine is partitioned preferentially into the negatively chargenerated inward membrane bending. B: On the "curved regions" of the membranes, where secretory granules started to dock or fuse into the cellular membranes, such induced inward membrane stretch mechanically counteracts the further docking or fusion forces of the secretory granules. This closes the opened pores, thereby inhibiting the further process of exocythe membranes, where the secretory granules are about to dock or fuse, the inward stretch of the membranes may rather facilitate the fusion process of the granules. However, olopatadine, which exerts membrane stabilizing effects, halts the further progression of exocytosis.
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inhibited the formation of the invaginated folds, suggesting that this drug counteracted the membrane surface deformation induced by exocytosis.
To examine the direct effect of olopatadine on the membrane surface deformation in them in the external solutions containing no drug or 1 mM olopatadine (Fig. 4) . Mast cells which consisted of the lipid bilayers (Fig. 4A) . However, in mast cells incubated in the olopatadine-containing external solution, there were some inward invaginations in the cellular membranes (Fig. 4B, arrows) , suggesting that the drug induced the inward membrane bending in mast cells.
Discussion
In previous in vitro studies using human conjunctival mast cells, olopatadine was demonstrated to exert inhibitory effects on the release of histamine [2] [3] [4] , in addition to its primary properties as a histamine receptor antagonist [1] . Mast cells that are derived from mucosal tissues, including conjunctiva, are known to produce larger amounts of chemical in previous studies, mast cells derived from human conjunctiva required extremely high doses of olopatadine to effectively elicit their inhibitory properties on exocytosis [2] [3] [4] . In the present study, using rat peritoneal mast cells, we provide electrophysiological evidence from our results, mast cells derived from peritoneal serosa required relatively lower doses of olopatadine than those derived from conjunctival mucosa [2] [3] [4] . According to previous in vivo olopatadine exerted inhibitory effects on exocytosis more effectively in mast cells derived triggered organ sclerosis.
In the present study, as we recently demonstrated with chlorpromazine [9] , olopatadine of secretory cells, the exocytotic process can be modulated by mechanical stimuli, such as changes in the membrane tension, shear stress, hydrostatic pressure and compression [8] . Therefore, the counteracting effect of olopatadine on the plasma membrane deformation in degranulating mast cells was thought to contribute to its inhibitory effect on the exocytotic process. Structurally, since olopatadine has both a carboxylic functional group and a tertiary amino group, this drug exists in different ionic forms depending upon the pH of the solution [19] . Since the pKa of the groups are 4.18 and 9.79, respectively, olopatadine usually exists as a zwitterion in the pH under a physiological condition [40] . However, since olopatadine was conjugated with hydrochloride in the present study, the external solution containing higher concentrations of olopatadine tended to be more acidic. Therefore, as is usually the case with the other anti-allergic reagents [10] , olopatadine was thought to be relatively cationic under the condition applied in the present study. Additionally, in previous studies using erythrocyte membranes, lipophilic olopatadine actually interacted directly with lipid layers of the plasma membranes [20, 41] . Therefore, this drug was thought to share similar pharmacological features with those of membrane amphipaths, and thus easily partitions into cellular membranes [20] . As previously demonstrated with chlorpromazine in both mast cells [9] and erythrocytes [42] , a positively charged membrane amphipath, such as cationic (Fig. 5A) , which was actually demonstrated by electron microscopy in the present study (Fig. 4) . On the "curved regions" of the membranes, where secretory granules started to dock or fuse into the cellular membranes (Fig. 5B top) , such induced inward stretch would mechanically counteract the further docking or fusion forces of the secretory granules, as we recently demonstrated with membrane amphipaths [9] . Consequently, this closes the opened pores of the mast cell membrane surface and part" of the membranes, where the secretory granules are about to dock or fuse (Fig. 5B top) , the inward stretch of the membranes may rather facilitate the soluble N-ethylmaleimidesensitive factor attachment protein receptor (SNARE)-induced fusion process of the granules anti-allergic drugs, including olopatadine, are known to exert membrane stabilizing effects exocytosis at this stage (Fig. 5B bottom) . According to previous patch-clamp studies, a rise in the [Ca 2+ ] i was one of the main triggers of exocytosis in mast cells [7, 11] actually generated inward membrane stretch in mast cells (Fig. 4) , and thus counteracted the exocytosis-induced deformation of the membrane surface (Fig. 5) . Therefore, this drug was membranes. As a result, such induced changes in the [Ca 2+ ] i may also have additional effects on the olopatadine-induced inhibition of exocytosis.
olopatadine dose-dependently inhibits the process of exocytosis in rat peritoneal mast cells. Such mast cell-stabilizing properties of olopatadine could be ascribed to its counteracting effects on the plasma membrane deformation in degranulating mast cells.
